Business and R&D Team

Business Leadership Team

Dr. Hans Soderlund
Director- Global Strategic Alliance

Dr Hans Soderlund is the Director-Global Strategic Alliance of Paras Biopharmaceuticals Finland Oy. He is also the Chairman of the Advisory Board of Paras Biopharmaceuticals Finland Oy. Dr Hans Soderlund is a veteran scientist and industry professional with over 40 years of experience and expertise in Genetic Engineering and Biotechnology. Dr Soderlund has more than 150 research publications and 27 independent inventions and patents. Dr Soderlund has a leading professional career with Academic institutions (Academy of Finland, SITRA, and VTT- Technical Research Centre of Finland) and Industry (Orion Corporation and two start-up companies). Dr Hans Soderlund is the Chairman of Board of University of Oulu, Finland. He has also acted as an expert judge in intellectual property issues in the Supreme Administrative Court of Finland.

Dr Hans Soderlund directs and leads the team Paras Biopharmaceuticals Finland Oy efforts for global strategic alliance for global foot-print for developing and bringing affordable and quality biopharmaceutical medicines to market, facilitated by cutting-edge technology innovations.

Dr John Coates
Mentor- Business Collaborations

Dr John Coates is our Mentor- Business Collaborations in Paras Biopharmaceuticals Finland Oy. Dr Coates has a long cherished and highly successful career. Following the achievement of his degree in Chemistry and a PhD sponsored by Cellmark, Astra Zeneca under Peter Sammes at the University of Surrey, Dr Coates joined the pharmaceutical industry initially in various sales and marketing positions, joining Merck Generics in 2001 as Technical Business Development Manager. In 2005, Dr Coates joined Schwarz Pharma as Business Development Manager and following the takeover by UCB in 2007, he moved to UCB’s Business Development team in 2008. In 2011 Dr Coates joined Wockhardt as their European Business Development Director,moving to Switzerland in 2011. Dr Coates is a Non- Executive Director of Bright Pharma, UK. Dr Coates participated in many in and out-licensing deals and has an extensive network of connections across Europe and beyond. He is an active member of the Pharmaceutical Licensing Group, having sat on the UK committee before moving to Switzerland.

Dr. Ashesh Kumar
Director- Biologics & Licensing

Dr Ashesh Kumar is the Director of Biologics & Licensing at Paras Biopharmaceuticals Finland Oy. Dr Kumar leads the team and is responsible for the organisation’s Biologics development program including the development of Biosimilars (for Osteoporosis and Metabolic diseases). Dr Kumar has successfully developed and out-licensed biosimilar technologies for scale up production of biologics and biosimilars in Europe and Asia. Prior to working in Paras, Dr Kumar was Head of Medipolis GMP Oy in Finland for six years and was Head of the cGMP Biopharma team in Europe where he guided a team which successfully developed and licensed a key biosimilar technology for scale up production in Europe. Dr Kumar’s group was responsible for carrying out more than Eight (8) Process Development and cGMP biopharmaceuticals development projects. Dr Kumar has a Ph.D. in Biosciences & Biotechnology from the Indian Institute of Technology- Roorkee, India.

Email :

Phone no : +358 400 207 380

Dr. Mark Jackson
Administration Lead & Research Associate

Dr. Mark Jackson undertakes a dual role within the Paras setup splitting his time between administrative duties and as a research associate specialising in injectable devices for the administration of drugs. Holding a PhD from the University of Manchester, England Dr Jackson came to Finland in 2007 and has previously worked at the University of Oulu. Mark brings many key skills to our team including versatility and flexibility as demonstrated by effective multitasking between his administrative and research roles.

Email :

Mr. Martti Särkelä
Business Advisor

With over 25 years of experience (including a M.Sc. (Tech) & Executive MBA) within sales, marketing, business development and internationalization, Martti Särkelä has associated with Paras Biopharmaceuticals Finland Oy since the company was established in 2013. Furthermore, during the last 15 years Martti has also worked with start-up and growth companies with business development, financing (public financiers and private & VC investors) and matchmaking.

Experienced in business development of high tech startups, and together with an in-depth knowledge of entrepreneurship support network and innovation system, Martti bring keys skills and expertise to the Team. Key areas of expertise include business idea evaluation, business strategies for startups, financial planning, assisting in getting public and private financing.

Dr. Alexander Kastaniotis
Senior Technical Associate

Dr. Alexander Kastaniotis is the latest addition to the Paras Biopharmaceuticals' team, taking up the role of Senior Technical Associate. Dr Alex brings a wealth of experience in yeast genetics, cell biology, developmental biology & molecular biology after graduating with a PhD from the University at Albany, State University of New York, USA. Dr Alex originally came to Finland in 2000 to join the Faculty of Biochemistry and Molecular Medicine at the University of Oulu in the area of mitochondrial fatty acid synthesis in yeast, mice and man. His research interest is focused on how metabolism controls the biogenesis of mitochondrial in lower and higher eukaryotes. Paras Biopharmaceuticals now has the pleasure of Dr Kastaniotis as part of their team.

Jyrki Perttunen
Chief Technical Officer (CTO)

Jyrki Perttunen is Chief Technical Officer (CTO) of Paras Biopharmaceuticals Finland Oy. Jyrki Perttunen is a process engineer by profession who graduated from the University of Oulu, Finland. Mr. Perttunen has more than 15 years of experience in process scale up and fermentation. Jyrki Perttunen is GMP trained and has undertaken several GMP projects for the production of recombinant therapeutic proteins. Mr. Perttunen is responsible for operations and project management, process scale up and Osteoporosis and Diabetes Drug Substance technology optimizations (upstream) and production.